Mark Sabag
Known title: EVP, International MarketsCIK: 0001721442
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▼ Sell | Open Market | 144,180 | $5.0M | 5/1/2026 | View on chart |
| TEVA | ▼ Sell | Open Market | 62,102 | $1.9M | 3/17/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,723 | — | 3/5/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 18,601 | — | 3/4/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 141,478 | — | 3/3/2026 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 118,724 | $2.2M | 12/9/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 118,724 | $3.4M | 12/9/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 98,168 | $2.8M | 12/9/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 337,915 | $6.1M | 5/8/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,765 | — | 3/5/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 18,601 | — | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 183,169 | — | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 177,626 | $2.9M | 2/12/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,764 | — | 3/5/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 58,133 | — | 3/5/2024 | View on chart |
| TEVA | ▼ Sell | Open Market | 100,000 | $1.4M | 3/5/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 24,900 | — | 3/3/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,599 | — | 2/28/2024 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,764 | — | 3/5/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,921 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 33,512 | — | 3/4/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,598 | — | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 50,242 | — | 2/28/2023 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 23,764 | — | 3/5/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,920 | — | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 43,358 | — | 3/4/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 20,598 | — | 2/28/2022 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 15,523 | — | 2/9/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.